Bellerophon Therapeutics Inc (NASDAQ:BLPH)’s stock price was down 15.8% on Thursday . The company traded as low as $0.47 and last traded at $0.48, approximately 942,800 shares traded hands during trading. An increase of 276% from the average daily volume of 250,626 shares. The stock had previously closed at $0.57.
A number of analysts have recently weighed in on BLPH shares. ValuEngine upgraded Bellerophon Therapeutics from a “sell” rating to a “hold” rating in a research report on Wednesday, October 2nd. Maxim Group reiterated a “buy” rating and set a $2.00 target price on shares of Bellerophon Therapeutics in a research report on Friday, August 9th.
The company has a current ratio of 2.64, a quick ratio of 2.64 and a debt-to-equity ratio of 0.15. The firm has a market capitalization of $40.66 million, a P/E ratio of -1.41 and a beta of -0.04. The firm has a 50-day moving average of $0.52 and a two-hundred day moving average of $0.61.
Hedge funds have recently made changes to their positions in the stock. LPL Financial LLC lifted its position in shares of Bellerophon Therapeutics by 22.1% during the 2nd quarter. LPL Financial LLC now owns 130,800 shares of the biotechnology company’s stock worth $78,000 after buying an additional 23,650 shares during the last quarter. Vanguard Group Inc. lifted its position in shares of Bellerophon Therapeutics by 15.9% during the 2nd quarter. Vanguard Group Inc. now owns 1,152,175 shares of the biotechnology company’s stock worth $690,000 after buying an additional 158,000 shares during the last quarter. Finally, Renaissance Technologies LLC lifted its position in shares of Bellerophon Therapeutics by 8.9% during the 2nd quarter. Renaissance Technologies LLC now owns 1,434,538 shares of the biotechnology company’s stock worth $860,000 after buying an additional 116,862 shares during the last quarter. Institutional investors and hedge funds own 53.36% of the company’s stock.
Bellerophon Therapeutics Company Profile (NASDAQ:BLPH)
Bellerophon Therapeutics, Inc is a clinical-stage therapeutics company, which focuses on developing innovative products at the intersection of drugs and devices that address significant unmet medical needs in the treatment of cardiopulmonary diseases. The company engages in two programs including INOpulse and BCM.
Featured Story: What is total return in investing?
Receive News & Ratings for Bellerophon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bellerophon Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.